期刊文献+

依那普利对糖尿病大鼠心肌超微结构的影响 被引量:2

Effect of enalapril on diabetic rat myocardial ultrastructure
暂未订购
导出
摘要 目的观察糖尿病大鼠心肌超微结构的动态变化及依那普利干预的效果。方法成年雄性Wistar大鼠分为:对照组、糖尿病组及糖尿病+依那普利组(每日2mg/kg灌胃,4月)。腹腔注射链脲佐菌素诱发糖尿病。分别于病程1,3,5月取其左心室组织块行透射电镜检查。结果糖尿病大鼠心肌超微结构自病程1月出现异常,随病程延长逐渐加重,依那普利治疗后大鼠心肌损害有所减轻。结论依那普利可改善糖尿病大鼠的心肌超微结构,这可能是ACEI类药物发挥糖尿病时心肌保护作用的病理机制。 Objective To observe the changes in the myocardial ultrastructure of diabetic rats and the effect of enalapril treatment. Methods Male Wistar rats were divided into 3 groups, namely the control group, diabetic group and enalapril intervention group. Diabetes was induced with peritoneal injection of streptozotocin in the latter 2 groups, and in enalapril group, the rats were treated with enalapril at the daily oral dose of 2 mg/kg for 1, 3 and 5 months after streptozotocin injection. Histological analysis of the left ventricular tissue was performed with transmission electron microscope 1, 3, and 5 months after establishment of diabetes. Results Onset of myocardial damages was observed 1 month after the development of diabetes in the rats with gradual time-dependent exacerbation. Enalapril treatment could partially reverse the myocardial destruction in the diabetic rats. Conclusion Enalapfil intervention may improve the ultrastructural pathology of the myocardium in diabetic rats, which is suggestive of the action mechanisms of angiotensin-converting enzyme inhibitors in myocardium preservation.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2007年第11期1726-1727,1730,共3页 Journal of Southern Medical University
基金 973国家重大基础发展研究项目(G20000569)
关键词 糖尿病 实验性 心肌超微结构 依那普利 diabetes, experimental myocardial ultrastructure enalapril
  • 相关文献

参考文献7

二级参考文献14

  • 1周晓朋,中华医学杂志,1990年,70卷,28页
  • 2蔡芳,中华医学杂志,1989年,69卷,276页
  • 3钟学礼,临床糖尿病学,1989年
  • 4团体著者,中华内科杂志,1979年,18卷,71页
  • 5Martinez A, Weaver C, Lopez J, et al. Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. [J]. Endocrinology, 1996, 137: 2626-32.
  • 6Hayashi M, Shimosawa T, Fujita T. Hyperglycemia increases vascular adrenomedullin expression [J]. Biochem Biophys Res Commun,1999,258: 453-6.
  • 7Hayashi S, Isaka Y, Fujita F. Plasma adrenomedullin in diabetes[J].Lancet, 1997, 350: 1449-50.
  • 8Martinez A, Elsasser TH, Bhathena SJ, et al. Is adrenomedullin a causal agent in some cases of type 2 diabetes [J]. Peptides, 1999, 20(12): 1471-8.
  • 9Kinoshita H, Kato K, Kuroki M, et al. Plasma adrenomedullin levels in patients with diabetes [J]. Diabetes Care, 2000, 23: 253-4.
  • 10Garcia-Unzueta MT, Montalban C, Pesquera C, et al. Plasma adreno-medullin levels in type 1 diabetes: relationship with clinical parameters [J]. Diabetes Care, 1998, 21: 999-1003.

共引文献58

同被引文献18

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部